HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nifedipine and esophageal dysfunction in progressive systemic sclerosis. A controlled manometric study.

Abstract
We evaluated the effect of the calcium channel blocking agent, nifedipine, on esophageal dysfunction in 15 patients with progressive systemic sclerosis, using a double-blind, randomized, crossover, placebo-controlled manometric study. Nifedipine significantly decreased lower esophageal sphincter pressure in these patients; this reduced lower esophageal sphincter pressure may cause gastroesophageal reflux. Thus, nifedipine may have detrimental effects on progressive systemic sclerosis patients.
AuthorsA Kahan, B Bour, D Couturier, B Amor, C J Menkes
JournalArthritis and rheumatism (Arthritis Rheum) Vol. 28 Issue 5 Pg. 490-5 (May 1985) ISSN: 0004-3591 [Print] United States
PMID3890864 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Nifedipine
Topics
  • Adolescent
  • Adult
  • Aged
  • Clinical Trials as Topic
  • Female
  • Gastroesophageal Reflux (chemically induced, physiopathology)
  • Humans
  • Male
  • Manometry
  • Middle Aged
  • Nifedipine (adverse effects)
  • Scleroderma, Systemic (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: